BIOMAT Database Logo BIOMAT Database Logo

Specific adoptive and passive immunotherapy be parabiosis for syngeneic mouse and rat tumors. 1976

C M Southam, and E B Bower, and V E Currie, and V I Babcock

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008748 Methylcholanthrene A carcinogen that is often used in experimental cancer studies. 20-Methylcholanthrene,3-Methylcholanthrene,20 Methylcholanthrene,3 Methylcholanthrene
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010227 Parabiosis The experimental joining of two individuals for the purpose of studying the effects of one on the other. Parabioses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012513 Sarcoma, Experimental Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA. EHS Tumor,Sarcoma, Engelbreth-Holm-Swarm,Sarcoma, Jensen,Experimental Sarcoma,Experimental Sarcomas,Sarcomas, Experimental,Engelbreth-Holm-Swarm Sarcoma,Jensen Sarcoma,Sarcoma, Engelbreth Holm Swarm,Tumor, EHS

Related Publications

C M Southam, and E B Bower, and V E Currie, and V I Babcock
Proceedings: Adoptive and passive immunotherapy.
January 1972, Proceedings. National Cancer Conference,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
April 1984, Journal of immunology (Baltimore, Md. : 1950),
C M Southam, and E B Bower, and V E Currie, and V I Babcock
Passive adoptive immunotherapy of low-immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes.
December 1984, International journal of cancer,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
Specific adoptive immunotherapy.
January 1989, Progress in clinical and biological research,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
An experimental approach to specific adoptive immunotherapy for malignant brain tumors.
November 1989, Nihon geka hokan. Archiv fur japanische Chirurgie,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
Specific adoptive immunotherapy by local transfer of cultured syngeneic spleen cells for mammary carcinoma in mice.
March 1983, Nihon geka hokan. Archiv fur japanische Chirurgie,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
Passive immunotherapy of established tumors with syngeneic antitumor serum in combination with immunopotentiators.
October 1977, Gan,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
Failure of adoptive immunization or parabiosis with hyperimmune syngeneic partners to abrogate long-term enhancement of rat kidney allografts.
October 1974, Transplantation,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
Adoptive immunotherapy of urologic tumors.
January 1989, Cancer treatment and research,
C M Southam, and E B Bower, and V E Currie, and V I Babcock
[Adoptive immunotherapy in malignant tumors].
January 2003, Vestnik Rossiiskoi akademii meditsinskikh nauk,
Copied contents to your clipboard!